U.S. markets open in 1 hour 39 minutes
  • S&P Futures

    3,895.50
    -3.25 (-0.08%)
     
  • Dow Futures

    31,501.00
    -8.00 (-0.03%)
     
  • Nasdaq Futures

    13,268.75
    -11.00 (-0.08%)
     
  • Russell 2000 Futures

    2,267.70
    -7.10 (-0.31%)
     
  • Crude Oil

    60.86
    +0.22 (+0.36%)
     
  • Gold

    1,729.00
    +6.00 (+0.35%)
     
  • Silver

    26.39
    -0.29 (-1.08%)
     
  • EUR/USD

    1.2037
    -0.0023 (-0.19%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.11
    -4.84 (-17.32%)
     
  • GBP/USD

    1.3921
    +0.0001 (+0.01%)
     
  • USD/JPY

    106.8630
    +0.1330 (+0.12%)
     
  • BTC-USD

    48,842.01
    +1,026.16 (+2.15%)
     
  • CMC Crypto 200

    982.80
    -3.85 (-0.39%)
     
  • FTSE 100

    6,635.61
    +47.08 (+0.71%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Ascendis Pharma A/S Announces First Quarter 2020 Financial Results and Business Update Conference Call on May 19

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

COPENHAGEN, Denmark, May 07, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Tuesday, May 19, 2020 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2020 financial results and provide a business update.

Conference Call Details

Date

Tuesday, May 19, 2020

Time

4:30 p.m. ET/1:30 p.m. Pacific Time

Dial In (U.S.)

844-290-3904

Dial In (International)

574-990-1036

Access Code

8295749

A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will be available on this website shortly after conclusion of the event for 30 days.

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon™ technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.

For more information, please visit www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (ii) our expectations regarding our ability to create new and potentially best-in-class therapies and (iii) our product pipeline and expansion into additional therapeutic areas. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; our ability to obtain additional funding, if needed, to support our business activities and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC on April 3, 2020. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. ©May 2020 Ascendis Pharma A/S.

Investor contact:
Patti Bank
Westwicke Partners
(415) 513-1284
patti.bank@westwicke.com
ir@ascendispharma.com

Media contact:
Ami Knoefler
Ascendis Pharma
(650) 739-9952
ack@ascendispharma.com